Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stock has been a huge winner in the past. A $10,000 investment in the biotech 10 years ago would be worth more than $200,000 today. Regeneron's shareholders have been on a roller …
Regeneron’s stock has gained 10.1% year to date outperforming the industry’s 4.7% rally. The company’s shares moved up in the pre-market trading and we expect shares to gain further momentum. The company reported earnings of $3.99 …
Regeneron (Nasdaq: REGN) is a large cap company that operates within the biotechnology industry. Its market cap is $43 billion today, and the total one-year return is 14.56% for shareholders. Regeneron stock is underperforming the …
After posting better-than-expected first-quarter results, Regeneron Pharmaceuticals (NASDAQ: REGN) stock enjoyed a nice bounce. The biotech announced solid sales for eye-disease drug Eylea and a strong launch for atopic dermatitis …
MCK has been the best S&P 500 Index (SPX) stock to own in May, going back 10 years. The security has averaged a one-month gain of 7.8%, and ended higher 90% of the time. REGN has also ended the month positive nine of the past 10 …
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stock has been a huge winner in the past. A $10,000 investment in the biotech 10 years ago would be worth more than $200,000 today. Regeneron's shareholders have been on a roller …
NWI1mon